Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00648336 | Fasting Study of Mercaptopurine 50 mg and Purinethol® Tablets 50 mg | PHASE1 | COMPLETED | 60 | — | — | Nov 1, 2003 | Dec 1, 2003 | Apr 24, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Mercaptopurine 50 mg |
| 2 | ACTIVE_COMPARATOR | Purinethol® Tablets 50 mg |
| Name | Type | Description |
|---|---|---|
| Mercaptopurine 50 mg | DRUG | 50mg, single dose fasting |
| Purinethol® Tablets 50 mg | DRUG | 50mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male 3. Volunteers are to be sterile (documentation required) or during the course of the study, from study screen until 3 months after study exit, non-sterile male volunteers must use a spermicide-containing barrier method of contraception to...